SEO URLwww.firestrike.ai/deals/neurocrine-group-limited-immedica-acquisition-2026-1
acquisitionAnnounced · Jan 14, 2026PharmaceuticalsSource · CredibleArticle · Factual
Immedica acquires Neurocrine Group Limited
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$65M
Target
Neurocrine Group Limited
Acquirer
Immedica
Full Acquisition
Status
Pending
Immedica agreed to acquire Neurocrine Group Limited. Reported deal value: $65M. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-01-14. Figures and status may change as filings and press coverage update.
January 14, 2026 Gibson Dunn is advising Immedica Pharma AB on the acquisition of Neurocrine Group Limited
Deal timeline
Announced
Jan 14, 2026 · gibsondunn.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $65M. Figures and status may change as sources update.
Sources: gibsondunn.com · Primary article · FireStrike proprietary index